Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Advanced Cancer × FP-1039 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1 Advanced Cancer 1

Interventions

Nivolumab 10 Surveys and Questionnaires 6 Bevacizumab 5 linrodostat 4 Standard of Care 4 Ipilimumab 4 Interviews as Topic 4 Docetaxel 4 temsirolimus 3 Sirolimus 3 Pemetrexed 3 Paclitaxel 3 Gemcitabine 3 Erlotinib Hydrochloride 3 Cetuximab 3 ARRY-334543 3 relatlimab 2 regorafenib 2 abemaciclib 2 Vorinostat 2 Trastuzumab 2 Sorafenib 2 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2 Magnetic Resonance Spectroscopy 2 Carboplatin 2 vorolanib 1 vistusertib 1 trametinib 1 tislelizumab 1 sargramostim 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00687505 2021-12-13

Safety Study of FP-1039 To Treat Cancer

Five Prime Therapeutics, Inc.

Phase 1 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡